Expanding The Proteome with ProFound's John Lepore, M.D.

Business Of Biotech

We love to hear from our listeners. Send us a message.

Flagship Pioneering’s ProFound Therapeutics is on to something, and it could be something big. It began with a simple question: What if more RNAs were being translated into proteins? Answering that question took ProFound deep into the translatome, where it’s now studying the full compendium of RNA sequences that are being translated into proteins. Along the way, the young company is gaining confidence that its research will reveal important insight into potential therapeutic protein targets and medicines. On this episode of the Business of Biotech, ProFound CEO and Flagship Pioneering CEO-Partner John Lepore, M.D. shares the company’s journey—and his—as a physician scientist-turned-founder.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Kapitel

1. BioExpo Live and Profound Therapeutics Discussion (00:00:00)

2. Career Evolution in Biopharma Discovery (00:05:10)

3. Transition From Big Pharma to Start-Up (00:12:28)

4. Innovative Protein Discovery and Pipeline Development (00:24:55)

5. Novel Targets in Oncology and Immunology (00:34:21)

6. Flagship-Pfizer Obesity Drug Development Partnership (00:42:59)

7. Computational Innovation in Biopharma Technology (00:50:45)